Sanofi, which manufacturers colon cancer drug Zaltrap, is suffering at the hands of generic competition. Sanofi, France’s largest drugmaker, reported a larger-than-expected, 34 per cent, decline in first-quarter profit, crimped by generic competition ...
[Published Irish Times - May 02 2013]